After heavy criticism from the scientific community, Janssen Pharmaceuticals updated its label for its interstitial cystitis drug, Elmiron, to include the risk of vision loss. The company had already made this change in Canada and Europe but failed to warn U.S. consumers until now.

In 2018, several studies showed a correlation between long-term use of Elmiron and pigmentary maculopathy. This began when Dr. Neiraj Jain wrote a letter to the editor of the Journal of Urology alerting readers to the new condition they were noticing among their patients.

Several of the doctor’s patients had difficulty reading and adapting to areas of dim light. Furthermore, the medical professionals found that these patients had subtle spots on the retina of their eyes.

Dr. Jain published a second case series with 10 patients with a median age of 59 years who were currently using Elmiron or had used it in the past. All the patients showed similar symptoms of retinal damage.

Despite these studies, Janssen Pharmaceuticals refused to change the product’s warning label to address these concerns. In 2019 the European Medicines Agency demanded that Elmiron warning label be updated to warn consumers of the risk. Janssen adhered to the request but still did not change the label in the U.S.

Finally, in June 2020, the company added the new warning about eye disease to its Elmiron label. The new label says that pigmentary changes in the retina “have been identified with long-term use of Elmiron.”

Elmiron users may be eligible for financial compensation through an Elmiron lawsuit. More claims are being filed every month.

 

More than $4 Billion Awarded in verdicts & negotiated settlements

SCROLL FOR MORE

$1.5
MILLION

CAR ACCIDENT

PERSONAL INJURY

$650
MILLION

PRADAXA INJURY LAWSUIT

PHARMACEUTICAL PRODUCT

$4
MILLION

TRAUMATIC BRAIN INJURY AT DAYCARE

PERSONAL INJURY

$2.4
BILLION

ACTOS INJURY LAWSUIT

PHARMACEUTICAL PRODUCT

$300
THOUSAND

SLIP AND FALL

PERSONAL INJURY

$1.5
BILLION

SYNGENTA CORN LAWSUIT

CHEMICAL EXPOSURE

$20
MILLION

TOXIC TORT INJURY

CHEMICAL EXPOSURE

$103.8
MILLION

COX-2 INHIBITORS INJURY

PHARMACEUTICAL PRODUCT

Client Reviews

SCROLL FOR MORE

They helped my elderly uncle receive compensation for the loss of his wife who was administered a dangerous drug. He consulted with this firm because of my personal recommendation and was very pleased with the compassion, attention to detail and response he received. Definitely recommend this firm for their 5 star service.

When I wanted to join the Xarelto class action lawsuit, I chose TorrHoerman Law from a search of a dozen or so law firm websites. I was impressed with the clarity of the information they presented. I gave them a call, and was again impressed, this time with the quality of our interactions.

TorHoerman Law is an awesome firm to represent anyone that has been involved in a case that someone has stated that it's too difficult to win. The entire firm makes you feel like you’re part of the family, Tor, Eric, Jake, Kristie, Chad, Tyler, Kathy and Steven are the best at what they do.

When I wanted to join the Xarelto class action lawsuit, I chose TorrHoerman Law from a search of a dozen or so law firm websites. I was impressed with the clarity of the information they presented. I gave them a call, and was again impressed, this time with the quality of our interactions.

When I wanted to join the Xarelto class action lawsuit, I chose TorrHoerman Law from a search of a dozen or so law firm websites. I was impressed with the clarity of the information they presented. I gave them a call, and was again impressed, this time with the quality of our interactions.

THANK YOU FOR YOUR MESSAGE

One of our associates will follow up with you shortly